Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
Dimitrios Goutas, Stamatios Theocharis, Gerasimos Tsourouflis
Diagnostics (2021) Vol. 11, Iss. 8, pp. 1346-1346
Open Access | Times Cited: 19

Showing 19 citing articles:

Now open: Evolving insights to the roles of lysine acetylation in chromatin organization and function
Joseph C. Y. Chen, Evangelia Koutelou, Sharon Dent
Molecular Cell (2022) Vol. 82, Iss. 4, pp. 716-727
Open Access | Times Cited: 57
HDAC Inhibition to Prime Immune Checkpoint Inhibitors
Édith Borcoman, Maud Kamal, Grégoire Marret, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 66-66
Open Access | Times Cited: 50
Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
Kostas Palamaris, Myrto Moutafi, Hariklia Gakiopoulou, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3660-3660
Open Access | Times Cited: 28
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 18
γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy
Stavros P. Papadakos, Konstantinos Arvanitakis, Ioanna Ε. Stergiou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1381-1381
Open Access | Times Cited: 7
HDAC/σ1R Dual-Ligand as a Targeted Melanoma Therapeutic
Claudia Giovanna Leotta, Carla Barbaraci, Jole Fiorito, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 179-179
Open Access
Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy
Ana Mafalda Rasteiro, Eva Sá e Lemos, Paula A. Oliveira, et al.
Veterinary Sciences (2022) Vol. 9, Iss. 3, pp. 107-107
Open Access | Times Cited: 16
The EPH/Ephrin System in Bone and Soft Tissue Sarcomas’ Pathogenesis and Therapy: New Advancements and a Literature Review
Argyris C. Hadjimichael, Alexandros Pergaris, Angelos Kaspiris, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5171-5171
Open Access | Times Cited: 13
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma
Adriana Amaro, Rosaria Gangemi, Laura Emionite, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 886-886
Open Access | Times Cited: 7
Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors
Kostas Palamaris, Luisa-Maria Tzimou, Georgia Levidou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4263-4263
Open Access | Times Cited: 7
Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations
Iason Psilopatis, Alexandros Pergaris, Kleio Vrettou, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 4045-4045
Open Access | Times Cited: 12
Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
Georgia Levidou, Paweł Gajdzis, Nathalie Cassoux, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4763-4763
Open Access | Times Cited: 14
Discovery of novel polysubstituted N -alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy
Ze Wang, Zhao Li, Bo Zhang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 5
Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4, and -5 in Ovarian Adenocarcinomas
Georgia Levidou, Dimitrios Arsenakis, Dimitrios I. Bolovis, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 947-947
Open Access | Times Cited: 1
Methionine 274 Is Not the Determining Factor for Selective Inhibition of Histone Deacetylase 8 (HDAC8) by L-Shaped Inhibitors
Niklas Jänsch, Kim Leoni Lang, Franz‐Josef Meyer‐Almes
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11775-11775
Open Access | Times Cited: 6
HDACs as an emerging target in endocrine tumors: a comprehensive review
E. Klieser, Bettina Neumayer, Pietro Di Fazio, et al.
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 2, pp. 143-154
Closed Access | Times Cited: 3
Histone deacetylase inhibitors regulate the oral cancer via PI3K/AKT signaling pathway
Mydhili Govindarasu, Lavanya Prathap, Rajakumar Govindasamy
Oral Oncology (2022) Vol. 135, pp. 106221-106221
Closed Access | Times Cited: 4
Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4 and -5 in Ovarian Adenocarcinomas
Georgia Levidou, Dimitrios Arsenakis, Dimitrios I. Bolovis, et al.
(2024)
Open Access
Differential Expression of DNA Methyltransferase (DNMT1 and DNMT3), Histone Deacetylase (HDAC1 and HDAC2), and Upstream Target Regulators MiR-145 and Mir-152 among Oral Cancers
Trevor Holloway, Karl Kingsley
Targets (2024) Vol. 2, Iss. 3, pp. 224-236
Open Access
Page 1

Scroll to top